What is Erasca?
Erasca is singularly focused on the discovery, development, and commercialization of therapies targeting cancers driven by RAS and MAPK pathway mutations. Recognizing the complex and promiscuous signaling of the RAS/MAPK pathway, the company adopts a holistic therapeutic strategy. This approach aims to comprehensively shut down the pathway by targeting multiple nodes and cooperative mechanisms in parallel, potentially offering synergistic benefits over single-target interventions. The company's commitment to this intricate area of oncology research positions it at the forefront of precision medicine.
How much funding has Erasca raised?
Erasca has raised a total of $564M across 3 funding rounds:
Series A
$64M
Series B
$200M
Share Placement
$300M
Series A (2019): $64M, investors not publicly disclosed
Series B (2020): $200M led by Invus, Terra Magnum Capital Partners, LifeSci Venture Partner, ARCH Venture Partners, Cormorant Asset Management , LLC, Colt Ventures, EDBI, and City Hill Ventures
Share Placement (2021): $300M, investors not publicly disclosed
Key Investors in Erasca
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments. EDBI's portfolio includes innovative companies in various fields, such as biotechnology, fintech, and telecommunications. Their mission is to catalyze growth and transform industries while uplifting lives.
What's next for Erasca?
With a significant enterprise-level funding context, Erasca is poised for accelerated growth and the advancement of its therapeutic pipeline. The recent strategic investment signals strong investor confidence in the company's innovative approach to tackling RAS- and MAPK pathway-driven cancers. Future developments will likely focus on progressing its three therapeutic strategies through clinical trials, with the ultimate goal of bringing effective combination therapies to patients. This strategic financing will be instrumental in scaling operations, expanding research and development efforts, and navigating the complex regulatory landscape to bring these much-needed treatments to market.
See full Erasca company page
